During the past decade, City Clinical Hospital #52 conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "City Clinical Hospital #52" #1 sponsor was "Celgene" with 4 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "AO GENERIUM" with 1 trials sponsored, "Abbott" with 1 trials sponsored and "Abbott Nutrition" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "City Clinical Hospital #52" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Harvard University" with 1 trials as a collaborator, "Incyte Corporation" with 1 trials as a collaborator, "Massachusetts General Hospital" with 1 trials as a collaborator and "Otsuka Pharmaceutical Co., Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "City Clinical Hospital #52" are "COVID-19" (3 trials), "Multiple Myeloma" (2 trials), "Atypical Hemolytic-Uremic Syndrome" (1 trials), "Chronic Kidney Disease (CKD) Stage 5" (1 trials) and "Coronavirus Disease 2019" (1 trials). Many other conditions were trialed in "City Clinical Hospital #52" in a lesser frequency.

Most popular intervention types in "City Clinical Hospital #52" are "Drug" (11 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Bortezomib" (2 trials), "Dexamethasone" (2 trials), "AG-221" (1 trials) and "Azacitidine" (1 trials). Other intervention names were less common.

The vast majority of trials in "City Clinical Hospital #52" are 13 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "City Clinical Hospital #52". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in City Clinical Hospital #52, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in City Clinical Hospital #52, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".